▎ 摘　　要

NOVELTY - Preparing a hepatocellular carcinoma-targeted functional graphene oxide medicine-loaded complex comprises mixing the functionalized graphene oxide with glypican-3 (GPC3)-small interfering RNA (siRNA) at according to the mass ratio of 3:5 through electrostatic action, and mixing graphene oxide/GPC3 siRNA with sorafenib according to the mass ratio of 8:5. USE - The graphene oxide medicine-loaded complex system is useful for treating a malignant growth of hepatocellular carcinoma by using molecular raking and chemotherapeutic medicines (claimed), significantly down-regulating the expression of liver cancer marker GPC3, inhibiting the proliferation and growth of hepatocellular carcinoma cell lines, and blocking the liver cancer cell cycle in G1 phase. ADVANTAGE - The system: has excellent dispersion, high biocompatibility, strong load capacity, and strong ability to kill liver cancer cells, and greater clinical application value efficiently; loads more medicines; and carries GPC3-siRNA and hepatocellular carcinoma chemotherapy medicines. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a graphene oxide medicine-loaded complex system prepared according to the above method from the anti-tumor gene GPC3 small interfering RNA, chemotherapeutic medicines and delivery carrier graphene oxide-polyethylene glycol-polyethylenimine polymers.